Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142870 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Bupropion in Treating Marijuana Dependent Individuals
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00142870 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 30 participants.
The verdict
NCT00142870, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. Bupropion (Zyban) is a medication currently used to treat withdrawal symptoms associated with tobacco use. The purpose of this study is to determine if bupropion will help individuals stop using marijuana.
Interventions
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142870
The ClinicalTrials.gov registry entry for NCT00142870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion is the first listed.
NCT00142870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142870 about?
NCT00142870 is a clinical study titled "Effectiveness of Bupropion in Treating Marijuana Dependent Individuals". A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. Bupropion (Zyban) is a medication currently used to treat withdrawal symptoms associated with tobacco use. The purpose of this study is to determine if bupropion will help individuals stop using ma...
What is the current status of trial NCT00142870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00142870?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT00142870?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.